Recent news highlights Syndax's clinical trial challenges, quarterly financial results, and ongoing development activities.

• Syndax's Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint, leading to a significant decline in share price [N2].
• The company reported a net loss and negative earnings per share for Q3 2026, with revenues lagging estimates in recent quarters [N8].
• Syndax held strong liquidity as of September 30, 2026, with $135.9 million in cash and $291.2 million in short-term investments, supporting ongoing operations [S2].
• Recent earnings calls and reports have detailed the company's financial performance and clinical development progress [N6][N7].

Syndax has developed and commercialized therapies such as REVUFORJ® and NIKTIMVO™, indicating capability in bringing products to market. Its collaborations with partners like Incyte Corporation and UCB Biopharma may enhance development and commercialization potential. The company holds substantial liquidity, supporting ongoing research and development activities. Successful future clinical trials and regulatory approvals could expand its product portfolio and market presence.

Recent clinical trial results, including the Phase 2 MAXPIRe trial of axatilimab missing its primary endpoint, have negatively impacted investor sentiment and share price. The company has reported consecutive quarterly losses with revenues lagging expectations, reflecting challenges in commercial execution or market adoption. Biopharmaceutical development carries high risks of regulatory setbacks, competitive pressures, and uncertain clinical outcomes, which could affect Syndax's financial performance and strategic plans.

Syndax's moat is primarily based on its proprietary biopharmaceutical product candidates and marketed therapies targeting cancer and fibrotic diseases. Its collaborations and licensing agreements with established pharmaceutical companies provide access to additional resources and expertise. However, the company faces typical industry risks including clinical trial outcomes, regulatory approvals, and competitive pressures in the biotech sector. The recent Phase 2 trial setback for axatilimab highlights the clinical development risks inherent in its business model.

• Clinical Trial Risk: Syndax's product candidates are subject to clinical trial outcomes, which have recently included a Phase 2 trial failure for axatilimab in idiopathic pulmonary fibrosis, posing risks to future development and commercialization.
• Financial Risk: The company has reported net losses and negative earnings per share, indicating ongoing operating expenses exceed revenues, which may require continued financing and careful cash management despite strong liquidity.
• Regulatory Risk: Obtaining and maintaining regulatory approvals for products and candidates is critical and uncertain, with potential delays or denials impacting business prospects.
• Market Adoption Risk: The commercial success of marketed products depends on physician and patient adoption, which can be influenced by competition, pricing, and reimbursement environments.

• Syndax Pharmaceuticals Inc is a biopharmaceutical company focused on cancer therapeutics and fibrotic diseases.
• The company reported a net loss of $49.4 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.55 per share as per its 10-Q filing dated November 2, 2026 [S2].
• As of September 30, 2026, Syndax held $135.9 million in cash and cash equivalents and $291.2 million in short-term investments, totaling $427.1 million in liquid assets [S2].
• The company had current assets of $567.4 million and current liabilities of $121.0 million as of September 30, 2026, resulting in a current ratio of 4.69 and a cash ratio of 3.53, indicating strong liquidity [S2].
• Syndax's recent clinical development includes the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis, which missed its primary endpoint, leading to a significant share price decline [N10, N11].
• The company has reported losses in recent quarters, including Q2 and Q3 2026, with revenues lagging estimates according to recent earnings reports [N8, N12].
• Syndax maintains collaborations and license agreements with companies such as UCB Biopharma and Vitae Pharmaceuticals, and has a collaboration with Incyte Corporation to develop and commercialize axatilimab [S1, S2].
• The company markets REVUFORJ® (revumenib) and NIKTIMVO™ (axatilimab-csfr) as part of its product portfolio [S1].
• Syndax is incorporated in Delaware and trades on the Nasdaq Stock Market under the ticker SNDX [S2].
• As of October 29, 2026, Syndax had approximately 90 million shares outstanding [S2].